Rectal cancer has, for most of modern medicine’s history, been categorized as a disease of older adults — something that showed up in screening conversations at 50, 60, 70. That assumption is being dismantled by a steady accumulation of data, and a new study presented at Digestive Disease Week 2026 adds one of the clearest pictures yet of how fast the shift is happening.
Researchers from SUNY Upstate Medical University analyzed CDC death records from 1999 through 2023 for adults aged 20 to 44. What they found is that deaths from early-onset colorectal cancer rose consistently throughout that entire period — and that rectal cancer mortality specifically is accelerating 2 to 3 times faster than colon cancer across every demographic. If the trend continues, rectal cancer deaths will exceed colon cancer deaths — already the leading cause of cancer-related death in people under 50 — by 2035.
“This is a medical crisis,” said Dr. Ben Schlechter, a gastrointestinal oncologist at Dana-Farber Cancer Institute. “This is not something that should be ignored.”
Not Hereditary, and Often No Risk Factors at All
The finding that most unsettles researchers is not the numbers themselves but what’s missing from the patient profiles. The bulk of early-onset rectal cancers are not hereditary, and a significant share of patients have what clinicians describe as “zero risk factors” — no obesity, no smoking, no family history.
“It’s not like there’s a new gene in the population,” Schlechter said. “This is something modern.” Whatever is driving the surge almost certainly began decades ago — an exposure in the 1960s or 1970s whose consequences are only becoming visible now. The leading hypothesis involves gut microbiome disruption, possibly from childhood sugar-sweetened beverage consumption, antibiotic overuse, or Western dietary shifts that weren’t present in prior generations at the same scale.
A Bacterial Toxin From Childhood
The most compelling emerging evidence points to a specific mechanism. A landmark study published in Nature in April 2025 analyzed 981 colorectal cancer genomes from patients across 11 countries and identified a toxin called colibactin, produced by certain strains of E. coli that colonize the gut, as a likely contributor to early-onset disease.
Colibactin leaves behind distinct patterns of DNA mutations in colon cells. Those mutation patterns were 3.3 times more common in patients diagnosed with colorectal cancer before age 40 than in those diagnosed after 70. Crucially, researchers were able to molecularly date when those mutations occurred — and the data pointed consistently to the first ten years of life. Children who were exposed to colibactin-producing E. coli in early childhood may be, as one researcher put it, “decades ahead of schedule” for developing cancer — getting it at 40 instead of 60.
Colibactin-producing bacteria can be acquired through contaminated water, food, or ordinary childhood contact. This doesn’t mean the exposure is unusual — many people have been exposed. What it means is that the mutation clock starts earlier than anyone previously appreciated.
Seven Months to Diagnosis
The mortality picture is made worse by a separate but compounding problem: diagnostic delay. Among adults under 50 with rectal cancer, 75% are diagnosed at an advanced stage. The average time from symptom onset to treatment is seven months. That delay isn’t primarily negligence — it’s a structural problem rooted in assumptions about who gets rectal cancer.
Symptoms like rectal bleeding, changes in bowel habits, or urgency are commonly attributed to hemorrhoids in younger patients. Clinicians trained to think of colorectal cancer as an older person’s disease may not immediately pursue workup in a 34-year-old who reports blood on toilet paper. Patients themselves may not push back. The result is that a significant share of young adults with rectal cancer spend months in a diagnostic limbo that directly affects their outcomes.
Hispanic Adults and Western States Are Hardest Hit
The new DDW study found meaningful variation in who is being affected most. Hispanic adults saw the steepest rise in rectal cancer deaths and had the fastest-growing mortality rates of any demographic group in the analysis. Adults in Western states also showed disproportionately elevated rates — a geographic pattern that researchers haven’t yet fully explained but that may relate to regional dietary patterns, healthcare access, or environmental exposures.
What the Screening Gap Looks Like
Current U.S. Preventive Services Task Force guidelines recommend colorectal cancer screening starting at age 45. That threshold was lowered from 50 in 2021 — an acknowledgment that onset ages were shifting. But the American Cancer Society and gastroenterologists treating younger patients argue that even 45 is too late for people with symptoms, and that the recommendation should not function as a reason to dismiss concerns in someone younger who is already experiencing them.
The practical guidance is direct: if something changes — persistent bowel habit shifts, rectal bleeding, unexplained urgency — see a doctor and ask explicitly whether colorectal cancer should be on the table. In a system still calibrated for an older patient profile, younger adults may need to advocate for themselves more forcefully than standard protocols currently prompt.